Technology has long infused health care with inspiration and hope. The trend held true on Wednesday when a trio of forward-thinking industry leaders shared their thoughts on the future of medicine at Fortune’s fourth-annual Brainstorm Health conference in San Diego.
But their discussion was also about wallets—specifically, in what technologies these investors are putting their money.
Legendary Silicon Valley investor Beth Seidenberg of Westlake Village BioPartners made news at the conference, revealing that cell therapy startup Tmunity has brought a product into human clinical trials that has knocked out multiple cancer genes.
“You read a lot about gene editing and CRISPR-Cas9 as a tool to knock-in or knock-out specific genes,” said the 14-year Kleiner Perkins veteran. “There’s a big question as to when is that ready for humans. I’m here to tell you it’s already in humans.”
The reveal came during a back-and-forth when the moderator, Fortune executive editor Adam Lashinsky, asked participants to weigh in on the impact of Amazon in health care. The e-commerce giant is a hot topic even at a conference focused on medical technology, since its entrance into the pharma space with its acquisition…